SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

JP Morgan Maintains Overweight on Kala Pharmaceuticals, Lowers Price Target to $14

JP Morgan maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Overweight and lowers the price target from $22 to $14.

Benzinga · -

JP Morgan maintains Kala Pharmaceuticals (NASDAQ:KALA) with a Overweight and lowers the price target from $22 to $14.